-
Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start Arthritis Res. Ther. (IF 4.9) Pub Date : 2023-09-29 Adrian Ciurea, Oliver Distler, Kenneth Kwok, Hyejin Jo, Lisy Wang, Tim Killeen, Caroline Ospelt, Mojca Frank Bertoncelj
Rheumatoid arthritis (RA) has a variable impact on different synovial joints, with inflammation being more commonly observed in some joints than others. Emerging evidence suggests that the anatomical variation in pathophysiology could result in differential responses to treatments across the joints, both within and between modes of action. This analysis aimed to characterize joint-specific responses
-
Association of knee and hip osteoarthritis with the risk of falls and fractures: a systematic review and meta-analysis Arthritis Res. Ther. (IF 4.9) Pub Date : 2023-09-29 Youyou Zhang, Xiaoxi Li, Yining Wang, Liru Ge, Faming Pan, Tania Winzenberg, Guoqi Cai
Studies evaluating the association of knee and hip osteoarthritis (OA) with falls and fractures have inconsistent findings. We aimed to investigate associations of symptomatic and radiographic knee and hip OA with risk of falls, recurrent falls, and fractures. We conducted an electronic search of databases from inception to February 2023. Two authors independently screened studies, extracted data,
-
Antiphospholipid antibody carriers and patients with quiescent antiphospholipid syndrome show persistent subclinical complement activation Rheumatology (IF 5.5) Pub Date : 2023-09-29 Margherita Zen, Marta Tonello, Maria Favaro, Teresa Del Ross, Antonia Calligaro, Alessandro Giollo, Filippo Vesentini, Ilenia Anna Gennaio, Federico Arru, Amelia Ruffatti, Andrea Doria
Objectives Complement activation has been advocated as one mechanism by which antiphospholipid antibodies (aPLs) can induce thrombosis. In patients with catastrophic aPL syndrome or re-thrombosis, enhanced complement activation was shown, even in quiescent phase of the disease. We aimed to assess complement activation and to investigate its association to clinical variables in aPL positive patients
-
Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept Arthritis Res. Ther. (IF 4.9) Pub Date : 2023-09-28 Louis Bessette, Boulos Haraoui, Emmanouil Rampakakis, Joanna Dembowy, Marc-Olivier Trépanier, Janet Pope
To compare a treat-to-target (T2T) approach and routine care (RC) in adults with active to severely active rheumatoid arthritis (RA) initiating subcutaneous abatacept. A 12-month cluster-randomized trial in active RA patients treated with abatacept was conducted. Physicians were randomized to RC or T2T with a primary endpoint of achieving sustained Clinical Disease Activity Index (CDAI) low disease
-
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases Rheumatology (IF 5.5) Pub Date : 2023-09-28 Ingrid Jyssum, Johanna E Gehin, Joseph Sexton, Eirik Klami Kristianslund, Yi Hu, David John Warren, Tore K Kvien, Espen A Haavardsholm, Silje Watterdal Syversen, Nils Bolstad, Guro Løvik Goll
Objectives To explore associations between serum adalimumab level, treatment response and drug survival in order to identify therapeutic drug levels for therapeutic drug monitoring of adalimumab. Also, to assess occurrence and risk factors of anti-drug antibody (ADAb) formation. Methods Non-trough adalimumab and ADAb levels were measured by automated fluorescence assays in serum collected after 3 months
-
Effects of oral contraceptives and menopausal hormone therapy on the risk of rheumatoid arthritis: a prospective cohort study Rheumatology (IF 5.5) Pub Date : 2023-09-28 Fatemeh Hadizadeh, Therese Johansson, Åsa Johansson, Torgny Karlsson, Weronica E Ek
Objectives Oral contraceptives (OC) and menopausal hormone therapy (MHT) contain exogenous sex hormones and are used by millions of women around the world. However, their effect on development of rheumatoid arthritis (RA) is still debated and the current literature suggests that they may exert opposite effects on the risk of RA. The present study aimed to estimate the effects of exogenous hormones
-
Addressing the unmet needs of transitional care in juvenile idiopathic arthritis Rheumatology (IF 5.5) Pub Date : 2023-09-28 Nihal Şahin, Hafize Emine Sönmez, Nuray Aktay Ayaz, Betül Sözeri
Objectives We aimed to comprehensively analyze the available literature to identify the unmet requirements in transitional programs tailored specifically for patients diagnosed with juvenile idiopathic arthritis (JIA). Methods According to published guidance on narrative reviews, a systematic review of the literature on transitional care in rheumatology was conducted. Pertinent documents were collected
-
Persisting mortality gap in systemic lupus erythematosus; a population-based study on juvenile- and adult-onset SLE in Norway 1999-2022 Rheumatology (IF 5.5) Pub Date : 2023-09-28 Sigrid Reppe Moe, Hilde Haukeland, Cathrine Brunborg, Antonela Botea, Nenad Damjanic, Gro Årthun Wivestad, Heidi Øvreås, Thea Bøe, Anniken Orre, Torhild Garen, Vibke Lilleby, Sella A Provan, Øyvind Molberg, Karoline Lerang
Objective To estimate mortality and survival rates of systemic lupus erythematosus (SLE) in a contemporary, population-based setting and assess potential influences by time, sex, ethnicity, classification criteria and age at diagnosis. Methods We assessed mortality and survival in the Nor-SLE cohort, which includes all chart-review confirmed SLE cases resident in Southeast Norway (population 2.9 million)
-
Efficacy and safety of anti-ınterleukin-1 treatment in familial Mediterranean fever patients: a systematic review and meta-analysis Rheumatology (IF 5.5) Pub Date : 2023-09-28 Berkay Kilic, Yelin Guler, Feyza N Azman, Ece Bostancı, Serdal Ugurlu
Objectives Familial Mediterranean fever (FMF) is the most common hereditary monogenic fever syndrome marked by recurrent attacks of fever and polyserositis. Colchicine is the current recommended first-line treatment for FMF. However, a small portion of FMF patients are unresponsive or intolerant to colchicine. Anti-interleukin-1 (anti-IL-1) agents are alternative treatment options for colchicine-resistant
-
Digital artery reconstruction with interposition vein graft: impact on secondary Raynaud's phenomenon Rheumatology (IF 5.5) Pub Date : 2023-09-28 Seong Oh Park, Hyung Woo Wang, Youngseo Han, Hee Chang Ahn
Objective Patients with secondary Raynaud’s phenomenon show a wide range of symptoms depending on the condition of vascular structures. If the symptoms are localized to specific fingers and angiography reveals a discrete segment of occlusion of a proper digital artery, we perform proper digital artery reconstruction with an interposition vein graft. The objective of this study was to evaluate the results
-
Evaluation of the ACR/EULAR 2022 criteria for classification of ANCA-associated vasculitis in a population-based cohort from Sweden Rheumatology (IF 5.5) Pub Date : 2023-09-28 Jens Rathmann, Mårten Segelmark, Aladdin J Mohammad
Objective To evaluate the ACR/EULAR 2022 criteria for AAV classification and compare it to the EMA algorithm and to classification based only on ANCA serology. Methods In the analysis, 374 cases (47% female) were classified according to EMA algorithm, ANCA serology, and ACR/EULAR criteria. The agreement rate was calculated using the kappa (κ) statistic. Results Under EMA, 192 patients were classified
-
Increased risk of osteoporosis and femoral neck fractures in patients with familial Mediterranean fever—a large retrospective cohort study Rheumatology (IF 5.5) Pub Date : 2023-09-27 Yonatan Shneor Patt, Niv Ben-Shabat, Lior Fisher, Kassem Sharif, Mohamad Arow, Simon Lassman, Abdulla Watad, Vita Skuja, Anan H Shtewe, Dennis McGonagle, Howard Amital
Objectives The direct impact of inflammatory conditions and their therapy with corticosteroids both contribute to an increased risk of osteoporosis with associated fractures. Familial-Mediterranean-Fever (FMF) is an autoinflammatory disorder not commonly treated with corticosteroids. Evidence regarding FMF association with osteoporosis and femur fractures is anecdotal. We aimed to evaluate the incidence
-
Patient factors and health outcomes associated with illness perceptions in people with gout Rheumatology (IF 5.5) Pub Date : 2023-09-27 Daniel Selvadurai, Matthew J Coleshill, Richard O Day, Nancy E Briggs, Marcel Schulz, Jennifer Reath, Eindra Aung
Objective Illness perceptions are views and beliefs formed in response to a health threat which may influence self-management behaviours and chronic disease outcomes. Despite effective medication, sub-optimal outcomes in gout are common. This study aimed to quantitatively investigate illness perceptions in gout to examine how illness perceptions relate to health outcomes. Methods Data were obtained
-
Anti-nuclear valosin-containing protein-like autoantibody is associated with calcinosis and higher risk of cancer in systemic sclerosis Rheumatology (IF 5.5) Pub Date : 2023-09-27 Janire Perurena-Prieto, Laura Viñas-Giménez, María Teresa Sanz-Martínez, Albert Selva-O’Callaghan, Eduardo Luis Callejas-Moraga, Roger Colobran, Alfredo Guillén- Del-Castillo, Carmen P Simeón-Aznar
Objectives Systemic sclerosis (SSc)-specific autoantibodies allow the diagnosis and predict the prognosis of SSc patients with different clinical characteristics. The aim of this study was to describe new SSc-related autoantibodies by a novel protein immunoprecipitation (IP) assay. Methods Serum samples and clinical data were collected from 307 SSc patients. Antinuclear autoantibodies were tested in
-
Physical function and sex differences in radiographic axial spondyloarthritis: a cross-sectional analysis on Bath Ankylosing Spondylitis Functional Index Arthritis Res. Ther. (IF 4.9) Pub Date : 2023-09-26 Magnus Hallström, Eva Klingberg, Anna Deminger, Jeannette Beckman Rehnman, Mats Geijer, Helena Forsblad-d’Elia
Physical function is an important determinant of health-related quality of life in radiographic axial spondyloarthritis patients (r-axSpA). To improve the basis of effective healthcare efforts, we aimed to investigate which demographic and disease-related factors that influence Bath Ankylosing Spondylitis Functional Index (BASFI) in r-axSpA patients overall and stratified by sex. Furthermore, we sought
-
2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate-to-Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is Ineffective Arthritis Rheumatol. (IF 13.3) Pub Date : 2023-09-25 Charles P. Hannon, Susan M. Goodman, Matthew S. Austin, Adolph Yates, Gordon Guyatt, Vinay K. Aggarwal, Joshua F. Baker, Phyllis Bass, Delamo Isaac Bekele, Danielle Dass, Hassan M. K. Ghomrawi, David S. Jevsevar, C. Kent Kwoh, Claudette M. Lajam, Charis F. Meng, Larry W. Moreland, Linda I. Suleiman, Jesse Wolfstadt, Kimberly Bartosiak, Nicholas A. Bedard, Jason L. Blevins, Anna Cohen-Rosenblum, P.
To develop evidence-based consensus recommendations for the optimal timing of hip and knee arthroplasty to improve patient-important outcomes including, but not limited to, pain, function, infection, hospitalization, and death at 1 year for patients with symptomatic and radiographic moderate-to-severe osteoarthritis or advanced symptomatic osteonecrosis with secondary arthritis of the hip or knee who
-
Automatic evaluation of atlantoaxial subluxation in rheumatoid arthritis by a deep learning model Arthritis Res. Ther. (IF 4.9) Pub Date : 2023-09-25 Yasutaka Okita, Toru Hirano, Bowen Wang, Yuta Nakashima, Saki Minoda, Hajime Nagahara, Atsushi Kumanogoh
This work aims to develop a deep learning model, assessing atlantoaxial subluxation (AAS) in rheumatoid arthritis (RA), which can often be ambiguous in clinical practice. We collected 4691 X-ray images of the cervical spine of the 906 patients with RA. Among these images, 3480 were used for training the deep learning model, 803 were used for validating the model during the training process, and the
-
MyD88 dimerization inhibitor ST2825 targets the aggressiveness of synovial fibroblasts in rheumatoid arthritis patients Arthritis Res. Ther. (IF 4.9) Pub Date : 2023-09-25 Sergio Ramirez-Perez, Rushi Vekariya, Surabhi Gautam, Itzel Viridiana Reyes-Perez, Hicham Drissi, Pallavi Bhattaram
Dimerization of the myeloid differentiation primary response 88 protein (MyD88) plays a pivotal role in the exacerbated response to innate immunity-dependent signaling in rheumatoid arthritis (RA). ST2825 is a highly specific inhibitor of MyD88 dimerization, previously shown to inhibit the pro-inflammatory gene expression in peripheral blood mononuclear cells from RA patients (RA PBMC). In this study
-
Identification of candidate genes and chemicals associated with osteoarthritis by transcriptome-wide association study and chemical-gene interaction analysis Arthritis Res. Ther. (IF 4.9) Pub Date : 2023-09-25 Lin Mei, Zhiming Zhang, Ruiqi Chen, Zhongyue Liu, Xiaolei Ren, Zhihong Li
Osteoarthritis (OA) is a common degenerative joint disease and causes chronic pain and disability to the elderly. Several risk factors are involved, such as aging, obesity, genetic susceptibility, and environmental factors. We conducted a transcriptome-wide association study (TWAS) and chemical-related gene set enrichment analysis (CGSEA) to investigate the susceptibility genes and environmental factors
-
Discovery of a novel missense variant in NLRP3 causing atypical CAPS with hearing loss as the primary presentation, responsive to anti-IL-1 therapy Arthritis Rheumatol. (IF 13.3) Pub Date : 2023-09-22 Merav Birk-Bachar, Hadar Cohen, Efrat Sofrin-Drucker, Nesia Kropach-Gilad, Naama Orenstein, Gabriel Lidzbarsky, Liora Kornreich, Rotem Tal, Gil Amarilyo, Yoel Levinsky, Meirav Sokolov, Eyal Raveh, Motti Gerlic, Liora Harel
-
The landscape of innate and adaptive immune cell subsets in patients with adult-onset Still’s disease Rheumatology (IF 5.5) Pub Date : 2023-09-25 Huihui Chi, Xinyue Hong, Ningqi Dai, Longfang Chen, Hao Zhang, Honglei Liu, Xiaobing Cheng, Junna Ye, Hui Shi, Qiongyi Hu, Jianfen Meng, Zhuochao Zhou, Jinchao Jia, Tingting Liu, Fan Wang, Mengyan Wang, Yuning Ma, Xia Chen, Yijun You, Dehao Zhu, Zihan Tang, Chengde Yang, Jialin Teng, Yutong Su, Yue Sun
Objective Adult-onset Still’s disease (AOSD) is a systemic autoinflammatory disorder. The understanding of the changes in adaptive immune cells and the crosstalk between innate and adaptive immune systems in AOSD is limited. This study aimed to examine the peripheral immune cell composition and inflammatory protein levels in AOSD patients. Methods Twenty-nine active AOSD patients were enrolled. Flow
-
Long-term effects of vitamin D supplementation and maintaining sufficient vitamin D on knee osteoarthritis over 5 years Arthritis Res. Ther. (IF 4.9) Pub Date : 2023-09-23 Zhiqiang Wang, Zhaohua Zhu, Feng Pan, Shuang Zheng, Venkat Parameswaran, Leigh Blizzard, Changhai Ding, Benny Antony
This study aimed to investigate the long-term effect of vitamin D supplementation compared to placebo over 5 years in participants with knee osteoarthritis (OA). We also aimed to describe the effect of maintaining sufficient serum vitamin D levels over five years in knee OA. Participants (n = 173) from the Hobart centre of the Vitamin D Effects on Osteoarthritis (VIDEO) trial were extensively followed
-
Cluster Analysis To Explore Clinical Subphenotypes Of Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss). J. Rheumatol. (IF 3.9) Pub Date : 2023-09-22 Emma Rubenstein, Carla Maldini, Augusto Vaglio, Federica Bello, Jan Phillip Bremer, Frank Moosig, Paolo Bottero, Alberto Pesci, Renato Alberto Sinico, Julian Grosskreutz, Claudia Feder, David Saadoun, Giorgio Trivioli, Federica Maritati, Barbara Rewerska, Wojciech Szczeklik, Paolo Fraticelli, Giuseppe Guida, Gina Gregorini, Gianluca Moroncini, Bernhard Hellmich, Jochen Zwerina, Matthieu Resche-Rigon
Previous studies suggested that distinct phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA) could be determined by presence or absence of antineutrophil cytoplasmic antibodies (ANCA), reflecting predominant vasculitic or eosinophilic processes, respectively. This study explored whether ANCA-based clusters or other clusters can be identified in EGPA.
-
Influence of the timing of biological treatment initiation on Juvenile Idiopathic Arthritis long-term outcomes Arthritis Res. Ther. (IF 4.9) Pub Date : 2023-09-21 Filipa Oliveira Ramos, Ana Maria Rodrigues, Ana Teresa Melo, Francisca Aguiar, Luísa Brites, Soraia Azevedo, Ana Catarina Duarte, José António Melo Gomes, Carolina Furtado, Ana Filipa Mourão, Graça Sequeira, Inês Cunha, Ricardo Figueira, Maria José Santos, João Eurico Fonseca
Juvenile idiopathic arthritis (JIA) treatment is aimed at inducing remission to prevent joint destruction and disability. However, it is unclear what is the long-term impact on health-related outcomes of the timing of biological disease-modifying antirheumatic drug (bDMARD) initiation in JIA. Our aim was to evaluate the long-term impact of the time between JIA onset and the initiation of a bDMARD in
-
3D chromosomal landscape reveals miR-146a dysfunctional enhancer in lupus and establishes a CRISPR-mediated approach to inhibit the IFN pathway Arthritis Rheumatol. (IF 13.3) Pub Date : 2023-09-20 Xinyi Zhu, Yutong Zhang, Zihang Yin, Zhizhong Ye, Yuting Qin, Zhaorui Cheng, Yiwei Shen, Zhihua Yin, Jianyang Ma, Yuanjia Tang, Huihua Ding, Ya Guo, Guojun Hou, Nan Shen
-
A Randomized, Controlled Neuroimaging Trial of Cognitive-Behavioral Therapy for Fibromyalgia Pain Arthritis Rheumatol. (IF 13.3) Pub Date : 2023-09-20 Jeungchan Lee, Asimina Lazaridou, Myrella Paschali, Marco L. Loggia, Michael P. Berry, Dan-Mikael Ellingsen, Kylie Isenburg, Alessandra Anzolin, Arvina Grahl, Ajay D. Wasan, Vitaly Napadow, Robert R. Edwards
Fibromyalgia (FM) is characterized by pervasive pain-related symptomatology and high levels of negative affect. Mind-body treatments such as cognitive-behavioral therapy (CBT) appear to foster improvement in FM via reductions in pain-related catastrophizing, a set of negative, pain-amplifying cognitive and emotional processes. However, the neural underpinnings of CBT's catastrophizing-reducing effects
-
Enhancing student understanding of rheumatic disease pathologies through augmented reality: findings from a multicentre trial Rheumatology (IF 5.5) Pub Date : 2023-09-21 Alexander Pfeil, Philipp Klemm, Axel J Hueber, Tobias Hoffmann, Tobias Weise, Peter Oelzner, Stefan Knop, Ulf Müller-Ladner, Uwe Lange, Gunter Wolf, Georg Schett, David Simon, Arnd Kleyer
Objective The possibility of combining real and virtual environments is driving the increased use of augmented reality (AR) in education, including medical training. The aim of this multicentre study was to evaluate the students’ perspective on the AR-based Rheumality GO!® app as a new teaching concept, presenting six real anonymised patient cases with rheumatoid arthritis (RA), psoriatic arthritis
-
Dual inhibition of glycolysis and glutaminolysis for synergistic therapy of rheumatoid arthritis Arthritis Res. Ther. (IF 4.9) Pub Date : 2023-09-20 Shanzay Ahmed, Christopher B. Mahony, Alyssa Torres, Jessica Murillo-Saich, Samuel Kemble, Martha Cedeno, Peter John, Attya Bhatti, Adam P. Croft, Monica Guma
Synovial fibroblasts in rheumatoid arthritis (RAFLS) exhibit a pathological aberration of glycolysis and glutaminolysis. Henceforth, we aimed to investigate if dual inhibition of these pathways by phytobiological compound c28MS has the potential of synergistic therapy for arthritis by targeting both glucose and glutamine metabolism. The presence of HK2 and GLS across various cell types and associated
-
Identification of potential susceptibility genes in patients with primary Sjögren’s syndrome-associated pulmonary arterial hypertension through whole exome sequencing Arthritis Res. Ther. (IF 4.9) Pub Date : 2023-09-20 Mucong Li, Yue Shi, Jiuliang Zhao, Qian Wang, Mengtao Li, Xiuli Zhao
Pulmonary arterial hypertension (PAH) is a rare complication of primary Sjögren’s syndrome (pSS). Several genes have proven to be associated with pSS and PAH. However, there is no study specifically addressing the genetic susceptibility in pSS combined with PAH. Thirty-four unrelated patients with pSS-PAH were recruited from April 2019 to July 2021 at Peking Union Medical College Hospital. Demographic
-
Determinants of health-related quality of life and global functioning and health in axSpA, pSpA, and PsA: results from the ASAS-PerSpA study Rheumatology (IF 5.5) Pub Date : 2023-09-20 Helena Santos, Ana R Henriques, Pedro M Machado, Clementina Lopez-Medina, Maxime Dougados, Helena Canhão, Ana M Rodrigues, Fernando M Pimentel-Santos
Objectives We aim to identify determinants of health-related quality of life (HRQoL) and global functioning and health (GH) in axial spondyloarthritis (axSpA), peripheral spondyloarthritis (pSpA), and psoriatic arthritis (PsA). Methods ASAS-perSpA study data were analyzed. Models for the three patient groups were performed separately to explore factors associated with HRQoL and GH, assessed by EQ-5D
-
Paraneoplastic arthritis: a series of 92 cases Rheumatology (IF 5.5) Pub Date : 2023-09-20 Bünyamin Kısacık, Fatih Albayrak, Mehmet Ali Balcı, Emrah Koc
Objectives Paraneoplastic arthritis (PA) is one of the paraneoplastic syndromes. Both laboratory and clinical findings similar to rheumatological diseases can be seen. In this study, we aimed to present the clinical and laboratory findings, malignancy type, and pathological diagnoses of patients with paraneoplastic arthritis. Methods In a multicentre retrospective study, 92 patients with PA from the
-
Re-thinking the perception of long-term opioid use in RMDs Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-09-18 Serge Perrot, Anne-Priscille Trouvin
Emerging data suggest that the frequency of long-term opioid use is high among individuals with rheumatic and musculoskeletal diseases, which is of concern given the risks of opioid misuse. But is long-term opioid use really that high or is the situation more complicated?
-
Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry Arthritis Res. Ther. (IF 4.9) Pub Date : 2023-09-19 Ju-Yang Jung, Eunyoung Lee, Ji-Won Kim, Chang-Hee Suh, Kichul Shin, Jinhyun Kim, Hyoun-Ah Kim
While the availability of biological or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) has improved outcomes for rheumatoid arthritis (RA) patients, there remains a subset of individuals who fail to achieve low disease activity or remission despite multiple cycles of b/tsDMARDs. This state is referred to as 'difficult-to-treat (D2T)' RA. Data from the Korean College of Rheumatology
-
Reproductive health in female patients with systemic sclerosis: a cross-sectional study Rheumatology (IF 5.5) Pub Date : 2023-09-19 Liyi Dai, Dan Xu, Xinyi Li, Sicheng Huang, Xiangyue Duan, Ai Zheng, Jing Yang, Jie Zhao, Lin Zeng, Rong Mu
Objectives To explore the status of reproductive health and related factors in female patients with systemic sclerosis (SSc). Methods A cross-sectional study was conducted among female patients from the Chinese Organization for Scleroderma through a questionnaire. Data on the status of reproductive health including fertility condition and menstrual status were obtained. The clinical and laboratory
-
Characteristics and course of patients with AA Amyloidosis: single center experience with 174 patients from Turkey Rheumatology (IF 5.5) Pub Date : 2023-09-19 Murat Bektas, Nevzat Koca, Emin Oguz, Selma Sari, Gizem Dagci, Burak Ince, Pelin Karaca Ozer, Besim Fazil Agargun, Yasemin Yalcinkaya, Bahar Artim-Esen, Lale Ocal, Murat Inanc, Ahmet Gul
Objectives This study aimed to evaluate the clinical, laboratory and genetic characteristics, and outcomes of patients with AA amyloidosis (AA-a). Methods Patients followed-up in a tertiary referral center in Turkey with the diagnosis of inflammatory rheumatic diseases and immunohistologically proven AA-a were included into the study and retrospectively analyzed. Results Among 184 patients with the
-
Do the features of juvenile psoriatic arthritis change according to age? A comprehensive evaluation of the PeRA Research Group Registry Rheumatology (IF 5.5) Pub Date : 2023-09-19 Şerife Gül Karadağ, Taner Coskuner, Fatma Gül Demirkan, Hafize Emine Sonmez, Semanur Ozdel, Mustafa Çakan, Gulcin Otar Yener, Kubra Ozturk, Ferhat Demir, Betül Sozeri, Nuray Aktay Ayaz
Objectives To describe the clinical features and treatment outcomes of children with juvenile psoriatic arthritis (JPsA) and to compare the distinct patterns of the disease between early-onset and late-onset age groups. Methods Patients with JPsA followed regularly for at least 6 months between 2010–2020 in 7 pediatric rheumatology centers in Turkey were included in the study. The demographic features
-
Old paradigms and new concepts in familial Mediterranean fever (FMF) – an update 2023 Rheumatology (IF 5.5) Pub Date : 2023-09-19 Eldad Ben-Chetrit
Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease characterized by recurrent attacks of fever and polyserositis. Its first description as a new entity was published by Siegal in 1945. Colchicine has been the treatment of choice for this disease since 1972. Significant progress has been made over the years in understanding FMF's clinical features, diagnosis, mode of inheritance
-
Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritis Rheumatology (IF 5.5) Pub Date : 2023-09-19 Clément Triaille, Pierre Quartier, Lien De Somer, Patrick Durez, Bernard Lauwerys, Patrick Verschueren, Peter C Taylor, Carine Wouters
Biological and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have revolutionized the management of multiple rheumatic inflammatory conditions. Amongst these, polyarticular juvenile idiopathic arthritis (pJIA) and rheumatoid arthritis (RA) display similarities in terms of disease pathophysiology and response pattern to b/tsDMARDs. Indeed, therapeutic efficacy of novel targeted
-
Can efficacy and safety data from clinical trials of rituximab in RA be extrapolated? Insights from 1984 patients from the AIR-PR Registry Rheumatology (IF 5.5) Pub Date : 2023-09-19 Yann Nguyen, Xavier Mariette, Jacques E Gottenberg, Michele Iudici, Jacques Morel, Olivier Vittecoq, Arnaud Constantin, Rene-Marc Flipo, Thierry Schaeverbeke, Jean Sibilia, Philippe Ravaud, Raphaël Porcher, Raphaèle Seror
Objectives To investigate whether the efficacy and safety data from drug-registration trials can be extrapolated to real-life RA patients receiving RTX. Methods The AIR-PR registry is a French multicentre, prospective cohort of RA patients treated with RTX in a real-life setting. We compared treatment responses at 12 months and serious AEs between eligible and non-eligible patients, by retrieving the
-
Progressive pulmonary fibrosis and its impact on survival in systemic sclerosis related interstitial lung disease Rheumatology (IF 5.5) Pub Date : 2023-09-19 Kathleen Morrisroe, Dylan Hansen, Wendy Stevens, Laura Ross, Joanne Sahhar, Gene-Siew Ngian, Catherine L Hill, Lauren Host, Jennifer Walker, Susanna Proudman, Mandana Nikpour
Objective To describe the frequency of progressive pulmonary fibrosis (PPF) in an incident cohort of systemic sclerosis (SSc) related interstitial lung disease (ILD) and its impact on survival. Methods Incident ILD was defined as the new development of characteristic fibrotic changes on chest HRCT scan. PPF was defined as per the 2022 American Thoracic Society. Determinants of PPF were identified using
-
Occupational impacts of early inflammatory arthritis: results from the National Early Inflammatory Arthritis Audit Rheumatology (IF 5.5) Pub Date : 2023-09-19 Katie Bechman, Emma Cook, Edward Alveyn, Abdullah Houssien, Martin Stevens, Mark D Russell, Maryam Adas, Paul Amlani-Hatcher, Sam Norton, Heidi Lempp, Joanna Ledingham, James Galloway, Karen Walker-Bone
Objectives Inflammatory arthritis (IA) causes significant work disability. Studies frequently fail to report important contextual information such as employment type. Our objective was to explore work participation, by gender and occupation type in early IA. Methods Data are from the National Early Inflammatory Arthritis Audit between 2018 and 2020. At diagnosis, clinicians collected information on
-
Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats Arthritis Res. Ther. (IF 4.9) Pub Date : 2023-09-18 Brittany D. Partain, Evelyn Bracho-Sanchez, Shaheen A. Farhadi, Elena G. Yarmola, Benjamin G. Keselowsky, Gregory A. Hudalla, Kyle D. Allen
Osteoarthritis (OA) is driven by low-grade inflammation, and controlling local inflammation may offer symptomatic relief. Here, we developed an indoleamine 2,3-dioxygenase and galectin-3 fusion protein (IDO-Gal3), where IDO increases the production of local anti-inflammatory metabolites and Gal3 binds carbohydrates to extend IDO’s joint residence time. In this study, we evaluated IDO-Gal3’s ability
-
Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study Arthritis Res. Ther. (IF 4.9) Pub Date : 2023-09-18 Xenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, Robert D. Inman, Hideto Kameda, Yihan Li, Xianwei Bu, Anna Shmagel, Peter Wung, In-Ho Song, Atul Deodhar
Upadacitinib, a Janus kinase inhibitor, has demonstrated efficacy and an acceptable safety profile in patients with ankylosing spondylitis (AS) in the phase III SELECT-AXIS programs. We report the 1-year efficacy and safety in patients with AS and an inadequate response to biologic disease-modifying antirheumatic drugs (bDMARD-IR) from the SELECT-AXIS 2 study. Patients ≥ 18 years with active AS who
-
Second and third TNF inhibitors in European patients with axial spondyloarthritis: Effectiveness and impact of the reason for switching Rheumatology (IF 5.5) Pub Date : 2023-09-18 Louise Linde, Lykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, Johan Karlsson Wallman, Daniela Di Giuseppe, Jakub Závada, Isabel Castrejon, Federico Díaz-Gonzalez, Ziga Rotar, Matija Tomšič, Bente Glintborg, Bjorn Gudbjornsson, Arni Jon Geirsson, Brigitte Michelsen, Eirik Klami Kristianslund, Maria José Santos, Anabela Barcelos, Dan Nordström, Kari K Eklund, Adrian Ciurea, Michael Nissen, Servet Akar
Objective To investigate real-world effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) and the association with 1) treatment line (second and third TNFi-series) and 2) reason for withdrawal from the preceding TNFi (lack of efficacy (LOE) versus adverse events (AE)). Methods Prospectively collected routine care data from 12 European registries were
-
Letter to the Editor: The impact of U.S. abortion policy on rheumatology clinical practice: a cross-sectional survey of rheumatologists Arthritis Rheumatol. (IF 13.3) Pub Date : 2023-09-14 Bonnie L Bermas, Irene Blanco, Ashira D Blazer, Megan EB Clowse, Cuoghi Edens, Rosalind Ramsey-Goldman, Greer Donley, Leslie Pierce, Catherine Wright, Mehret Birru Talabi
-
Oxidative stress by the mitochondrial monoamine oxidase B mediates calcium pyrophosphate crystal-induced arthritis Arthritis Rheumatol. (IF 13.3) Pub Date : 2023-09-11 Francisca C. Venegas, Ricardo Sánchez-Rodríguez, Roberto Luisetto, Roberta Angioni, Antonella Viola, Marcella Canton
-
Derivation and Internal Validation of a Disease-specific Cardiovascular Risk Prediction Model for Patients with Psoriatic Arthritis and Psoriasis Arthritis Rheumatol. (IF 13.3) Pub Date : 2023-09-11 Keith Colaco, Ker-Ai Lee, Shadi Akhtari, Raz Winer, Vinod Chandran, Paula Harvey, Richard J. Cook, Vincent Piguet, Dafna D. Gladman, Lihi Eder
-
Causal associations of Sjögren’s syndrome with cancers: a two-sample Mendelian randomization study Arthritis Res. Ther. (IF 4.9) Pub Date : 2023-09-15 Yiwei Jia, Peizhuo Yao, Jia Li, Xinyu Wei, Xuanyu Liu, Huizi Wu, Weiwei Wang, Cong Feng, Chaofan Li, Yu Zhang, Yifan Cai, Shuqun Zhang, Xingcong Ma
Several observational studies have explored the associations between Sjögren’s syndrome (SS) and certain cancers. Nevertheless, the causal relationships remain unclear. Mendelian randomization (MR) method was used to investigate the causality between SS and different types of cancers. We conducted the two-sample Mendelian randomization with the public genome-wide association studies (GWASs) summary
-
Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study Arthritis Res. Ther. (IF 4.9) Pub Date : 2023-09-15 Georg Schett, Warner Chen, Sheng Gao, Soumya D. Chakravarty, May Shawi, Frederic Lavie, Miriam Zimmermann, Mohamed Sharaf, Laura C. Coates, Stefan Siebert
Correction: Arthritis Res Ther 25, 150 (2023) https://doi.org/10.1186/s13075-023-03125-4 Following publication of the original article [1], the authors reported that the corrections were not carried out during the revisions. The corrections are provided below and the changes have been set in bold typeface. Author details: 1 Department of Medicine 3 – Rheumatology and Immunology, Universitatsklinikum
-
Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial Arthritis Res. Ther. (IF 4.9) Pub Date : 2023-09-15 William Tillett, Alexander Egeberg, Enikö Sonkoly, Patricia Gorecki, Anna Tjärnlund, Jozefien Buyze, Sven Wegner, Dennis McGonagle
Nail psoriasis is a common, physiologically, and psychologically disruptive, and yet often under-treated manifestation of psoriasis. The objectives of this analysis were to investigate the trajectory of nail psoriasis, a risk factor for psoriatic arthritis (PsA), with guselkumab vs adalimumab treatment followed by withdrawal, and determine characteristics associated with nail response in patients treated
-
Long term prognosis of anti-melanoma differentiation-associated gene 5-positive dermatomyositis with interstitial lung disease. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Tsuneo Sasai, Ran Nakashima, Hideaki Tsuji, Toshiki Nakajima, Yoshitaka Imura, Yusuke Yoshida, Shintaro Hirata, Mirei Shirakashi, Ryosuke Hiwa, Koji Kitagori, Shuji Akizuki, Hajime Yoshifuji, Tsuneyo Mimori, Akio Morinobu
Anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis with interstitial lung disease (DM-ILD) progresses rapidly and has a poor prognosis. Recently, we reported the efficacy of a combination therapy comprising high-dose glucocorticoids (GCs), calcineurin inhibitors (CNIs), and intravenous cyclophosphamide (IVCY) in a multicenter clinical trial (UMIN000014344). In the present
-
Features of Knee and Multi-joint Osteoarthritis by Sex and Race/Ethnicity: A Preliminary Analysis in the Johnston County Health Study. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Sherwin Novin, Carolina Alvarez, Jordan Renner, Yvonne Golightly, Amanda Nelson
To evaluate knee and multi-joint osteoarthritis (KOA and MJOA) and compare features by sex and race/ethnicity in a population-based cohort.
-
Changes in TNF inhibitor drug survival in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis over 15 years. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Ingrid Visman, Sadaf Atiqi, Maarten Boers, Jos Twisk, Michael Nurmohamed
To study changes in retention of first biologic DMARD therapy over a period of 15 years in an inception cohort of patients with Rheumatoid arthritis (RA), Psoriatic arthritis (PsA) and Ankylosing Spondylitis (AS).
-
The Journal of Rheumatology: A Strong Supporter of Pediatric Rheumatology. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Ronald M Laxer
I am very much enjoying your trip down memory lane looking back at important articles in The Journal of Rheumatology I was especially interested in your "Looking Back at the 1990s." I would like to point out an important milestone in The Journal that also took place in the 1990s, that is, the establishment of Pediatric Rheumatology as a section in The Journal.
-
Unequal Treatment: Physical Therapy Utilization in Rheumatoid Arthritis. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Jennifer L Barton
The American College of Rheumatology (ACR) 2022 guidelines for nonpharmacologic management of rheumatoid arthritis (RA) include a conditional recommendation for physical therapy (PT).1 Known disparities by socioeconomic status (SES) and race and ethnicity in RA prevalence, patient-reported outcomes of function, disease activity, and access exist and persist over time.2,3.
-
Thoracic Clavicular Gout. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Zheng Liao, Li Deng, Xiaowen Luo, Zhenhua Wen
Gout is a common condition characterized by the deposition of monosodium urate (MSU) crystals in articular and nonarticular structures.1 The formation of MSU crystals has been reported in atypical locations such as the eye, nose, spine, and viscera.2.
-
Clinical improvement in early onset interstitial lung disease using rituximab in children with anti-MDA5 positive juvenile dermatomyositis. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Malki Peskin, Marilyn Mostowy, Jennifer Velez, Megan Perron, Jessica Kurian, Dawn M Wahezi
Children with juvenile dermatomyositis (JDM) and antibodies to melanoma differentiation associated gene 5 (anti-MDA5) are at increased risk of severe disease complications, including interstitial lung disease (ILD). Data regarding treatment of disease complications in this patient population is limited. In this study, we examined the disease course of children with JDM and anti-MDA5 antibodies before
-
Military Report From the Front. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Dariusz Wołodźko
there is no front line everything is war front territory of the organism under attack enemy takes control.
-
Chew on This: The Afterbite of Temporomandibular Joint Involvement in Adults With Juvenile Idiopathic Arthritis. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Evelyn Victoria Rozenblyum, Mercedes Olivia Chan, Natasha Kaur Gakhal
Juvenile idiopathic arthritis (JIA) is a chronic autoimmune disease that continues into adulthood in approximately 50% of patients.1 Growth considerations are unique to pediatric-onset disease and can lead to permanent joint damage.
-
Complement proteins L-ficolin and M-ficolin are increased in axial spondyloarthritis patients and decrease after TNF-inhibitor treatment. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Clara Elbæk Mistegaard, Anne Troldborg, Annette Hansen, Steffen Thiel, Anne Grethe Jurik, Rosa M Kiil, Alice A Christiansen, Berit Schiøttz-Christensen, Oliver Hendricks, Susanne Juhl Pedersen, Inge Juul Sørensen, Mikkel Østergaard, Anne Gitte Loft
We have previously reported elevated levels of the complement lectin pathway proteins L-ficolin and H-ficolin in axial spondyloarthritis (axSpA) patients compared with healthy controls. The aim of this study was to investigate these biomarkers in a cross-sectional cohort of patients suffering from low back pain (LBP). Furthermore, we aimed to investigate changes in lectin pathway protein levels after